Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities

(Cell Reports 14, 979–990; February 9, 2016) In the originally published version of this article, there was an inadvertent duplication of the single agent controls in Figure 1E. A corrected version of the figure panel is provided here. The authors regret this error. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique VulnerabilitiesFranco et al.Cell ReportsJanuary 21, 2016In BriefCDK4/6 inhibitors are potent inhibitors of cell cycle that are employed clinically. Franco et al. report that the inhibition of CDK4/6 in pancreatic cancer models reprograms metabolism through a pathway involving the RB tumor suppressor and MTOR activation. These findings demonstrate specific metabolic adaptations to this class of therapeutic agents and delineate vulnerabilities for future therapeutic intervention. Full-Text PDF Open Access